A Phase 2 Study to Evaluate the Safety and Efficacy of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Cemdomespib (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Adverse reactions; Therapeutic Use
- Acronyms CYPRESS
- Sponsors Biogen; Reata Pharmaceuticals
- 11 Oct 2023 This study was previously posted by Reata Pharmaceuticals. In September 2023, sponsorship of the trial was transferred to Biogen.
- 13 Sep 2023 Status changed from not yet recruiting to recruiting.
- 31 May 2023 Status changed from planning to not yet recruiting.